FOLFIRI Plus Ramucirumab vs Paclitaxel Plus Ramucirumab as Second-Line Therapy for Advanced/Metastatic Gastroesophageal Adenocarcinoma With/Without Prior Docetaxel
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
Eur. J. Cancer 2022 Feb 21;165(xx)48-57, S Lorenzen, P Thuss-Patience, C Pauligk, E Gökkurt, T Ettrich, F Lordick, M Stahl, P Reichardt, M Sökler, D Pink, S Probst, A Hinke, TO Goetze, SE Al-BatranFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.